SEROPREVALENCE OF ANTI-MEASLES IGG IN THE POPULATION OF KHARKIV REGION IN 2018-2019
Immunology and Allergology: Science and Practice · 2019
DOI: 10.37321/immunology.2019.04-03 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology and Allergology: Science and Practice, 2019. Verfasst von Igor Yudin und 2 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
The aim of this study was to evaluate herd immunity against measles in different age groups of the Kharkiv region of Ukraine’s population. Materials and methods. Seroprevalence of specific IgG antibodies was studied among different age groups of the Kharkiv region population from February 2018 to July 2019 by ELISA method.
Results
A number of 6564 sera samples were processed. The overall seropositivity level was 91.3%; negative results were 5.3% and 3.3% equivocal. The highest seropositivity for IgG (> 98%) was in people aged 50 years and older. The lowest seropositivity rates were observed in the cohorts of 20-29 years (87.2%), 30-39 years (86.9%), and 40-49 years (91.1%).
Conclusions
Measles-susceptible populations were identified for which new prevention strategies should be applied in the form of personalized vaccination campaigns to increase herd immunity.
Zitieren
APA
Yudin, I., Kuchma, I., & Voliansky, A. (2019). SEROPREVALENCE OF ANTI-MEASLES IGG IN THE POPULATION OF KHARKIV REGION IN 2018-2019. Immunology and Allergology: Science and Practice. https://doi.org/10.37321/immunology.2019.04-03
Vancouver
Yudin I, Kuchma I, Voliansky A. SEROPREVALENCE OF ANTI-MEASLES IGG IN THE POPULATION OF KHARKIV REGION IN 2018-2019. Immunology and Allergology: Science and Practice. 2019. doi:10.37321/immunology.2019.04-03
BibTeX
@article{Yudin2019,
author = {Yudin, Igor and Kuchma, Irina and Voliansky, Andriy},
title = {SEROPREVALENCE OF ANTI-MEASLES IGG IN THE POPULATION OF KHARKIV REGION IN 2018-2019},
journal = {Immunology and Allergology: Science and Practice},
year = {2019},
doi = {10.37321/immunology.2019.04-03}
}
EUVIMED